Shares of bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) traded down 19.9% during mid-day trading on Thursday . The company traded as low as $0.03 and last traded at $0.26. 812 shares changed hands during trading, a decline of 63% from the average session volume of 2,171 shares. The stock had previously closed at $0.33.
bioAffinity Technologies Stock Performance
The firm's 50-day moving average is $0.44.
Get
bioAffinity Technologies alerts:
Institutional Investors Weigh In On bioAffinity Technologies
An institutional investor recently bought a new position in bioAffinity Technologies stock. Armistice Capital LLC purchased a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAFW – Get Rating) in the third quarter, according to its most recent filing with the SEC. The firm purchased 204,082 shares of the company's stock, valued at approximately $72,000.
bioAffinity Technologies Company Profile
(Get Rating)
bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level.
See Also
- Get a free copy of the StockNews.com research report on bioAffinity Technologies (BIAFW)
- MarketBeat: Week in Review 01/02-01/06
- Why is the CrowdStrike Stock Price Struggling?
- Four Undervalued Healthcare Stocks for 2023
- WWE Stock: Vince McMahon Wants Back In The Show
- NVIDIA Is Bottoming But Don't Buy It Just Yet
Receive News & Ratings for bioAffinity Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bioAffinity Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
生物親和技術公司(納斯達克代碼:BIAFW-GET Rating)的股價週四午盤下跌19.9%。該公司股價低至0.03美元,最新報0.26美元。812股股票在交易中易手,較2,171股的平均成交量下降了63%。該股此前收盤價為0.33美元。
生物親和力科技股表現
該公司的50日移動均線切入位為0.44美元。
到達
生物親和技術警報:
機構投資者看好生物親和技術
一家機構投資者最近買入了BioAffity Technologies股票的新頭寸。停戰資本有限責任公司在第三季度購買了生物親和技術公司(納斯達克:BIAFW-GET Rating)的新股,根據其最近提交給美國證券交易委員會的檔案。該公司購買了204,082股該公司股票,價值約72,000美元。
生物親和技術公司簡介
(獲取評級)
生物親和技術公司是一家生物技術公司,致力於開發非侵入性診斷測試和靶向癌症療法。該公司提供CyPath肺部診斷測試,用於早期發現肺癌。它還研究在細胞水準上治療癌症的靶向療法。
另請參閱
- 免費獲取StockNews.com關於生物親和技術的研究報告(BIAFW)
- MarketBeat:回顧中的一週01/02-01/06
- 為什麼CrowdStrike的股價舉步維艱?
- 2023年四隻被低估的醫療保健股票
- WWE股票:文斯·麥克馬洪想要重返節目
- NVIDIA正在觸底,但現在還不能買入
接受《生物親和技術日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊,接收最新新聞和分析師對BioAffity Technologies及相關公司的評級的每日摘要。